Marker Therapeutics (NASDAQ:MRKR) Stock Rating Upgraded by Zacks Research

Marker Therapeutics (NASDAQ:MRKR) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday, Zacks reports.

Several other research firms have also weighed in on MRKR. Weiss Ratings lowered Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Marker Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Marker Therapeutics Price Performance

Shares of MRKR stock traded up $0.12 during trading hours on Thursday, reaching $1.04. The company had a trading volume of 1,145,148 shares, compared to its average volume of 86,015. The company has a 50 day moving average of $1.17 and a 200 day moving average of $1.33. The firm has a market cap of $17.34 million, a price-to-earnings ratio of -2.54 and a beta of 1.53. Marker Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.46.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.16. As a group, sell-side analysts forecast that Marker Therapeutics will post -0.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Renaissance Technologies LLC lifted its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 41.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,294 shares of the company’s stock after buying an additional 51,644 shares during the period. Renaissance Technologies LLC owned about 1.05% of Marker Therapeutics worth $228,000 as of its most recent SEC filing. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s approach uses tumor-specific T cells designed to recognize multiple tumor-associated antigens, with the goal of addressing the heterogeneity of solid tumors and potentially reducing the likelihood of treatment resistance.

Marker’s lead program is MT-601, an autologous multi-antigen-specific T-cell therapy being evaluated for pancreatic ductal adenocarcinoma.